Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk

Dow Jones

Jan 16

1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. "We see upside to Wegovy pill consensus sales estimates." Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 06:30 ET (11:30 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603960230"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603960230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603960230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603960230","market":"sg","top_or_hot":-1,"title":"Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603960230","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603960230","pubTimestamp":1768563000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股"},"translate_title":"诺和诺德的Wegovy药丸今年销售额可能达到10亿美元——市场讨论","themeId":"d806896b6091b132ff78b81fa73d2804","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 06:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}